Ark. Supreme Court Won't Rehear $1.2B Risperdal Case
The Arkansas Supreme Court on Thursday declined to reconsider its decision freeing Johnson & Johnson and a subsidiary from a $1.2 billion fine over their marketing of the antipsychotic drug Risperdal,...To view the full article, register now.
Already a subscriber? Click here to view full article